دورية أكاديمية
أعرض في EDS

Survival among patients with untreated metastatic breast cancer: "What if I do nothing?"

التفاصيل البيبلوغرافية
العنوان: Survival among patients with untreated metastatic breast cancer: "What if I do nothing?"
المؤلفون: Plichta JK; Department of Surgery, Duke University Medical Center, DUMC 3513, Durham, NC, 27710, USA. Jennifer.Plichta@duke.edu.; Department of Population Health Sciences, Duke University Medical Center, Durham, NC, USA. Jennifer.Plichta@duke.edu.; Duke Cancer Institute, Durham, NC, USA. Jennifer.Plichta@duke.edu., Thomas SM; Duke Cancer Institute, Durham, NC, USA.; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Wang X; Department of Surgery, Loyola University Medical Center, Maywood, IL, USA., McDuff SGR; Duke Cancer Institute, Durham, NC, USA.; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA., Kimmick G; Duke Cancer Institute, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Hwang ES; Department of Surgery, Duke University Medical Center, DUMC 3513, Durham, NC, 27710, USA.; Duke Cancer Institute, Durham, NC, USA.
المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (2), pp. 333-347. Date of Electronic Publication: 2024 Mar 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
مواضيع طبية MeSH: Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/therapy , Neoplasm Metastasis*, Humans ; Female ; Middle Aged ; Aged ; Adult ; Prognosis ; Kaplan-Meier Estimate ; Aged, 80 and over ; Proportional Hazards Models ; Comorbidity
مستخلص: Purpose: We sought to assess survival outcomes of patients with de novo metastatic breast cancer (dnMBC) who did not receive treatment irrespective of the reason.
Methods: Adults with dnMBC were selected from the NCDB (2010-2016) and stratified based on receipt of treatment (treated = received at least one treatment and untreated = received no treatments). Overall survival (OS) was estimated using the Kaplan-Meier method, and groups were compared. Cox proportional hazards models were used to identify factors associated with OS.
Results: Of the 53,240 patients with dnMBC, 92.1% received at least one treatment (treated), and 7.9% had no documented treatments, irrespective of the reason (untreated). Untreated patients were more likely to be older (median 68 y vs 61 y, p < 0.001), have higher comorbidity scores (p < 0.001), have triple-negative disease (17.8% vs 12.6%), and a higher disease burden (≥ 2 metastatic sites: 38.2% untreated vs 29.2% treated, p < 0.001). The median unadjusted OS in the untreated subgroup was 2.5 mo versus 36.4 mo in the treated subgroup (p < 0.001). After adjustment, variables associated with a worse OS in the untreated cohort included older age, higher comorbidity scores, higher tumor grade, and triple-negative (vs HR + /HER2-) subtype (all p < 0.05), while the number of metastatic sites was not associated with survival.
Conclusions: Patients with dnMBC who do not receive treatment are more likely to be older, present with comorbid conditions, and have clinically aggressive disease. Similar to those who do receive treatment, survival in an untreated population is associated with select patient and disease characteristics. However, the prognosis for untreated dnMBC is dismal.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Am J Surg. 2022 Jan;223(1):81-93. (PMID: 34325907)
Surgery. 2002 Oct;132(4):620-6; discussion 626-7. (PMID: 12407345)
Med Oncol. 2015 Feb;32(2):466. (PMID: 25588926)
JCO Glob Oncol. 2023 May;9:e2200393. (PMID: 37167575)
Ann Surg Oncol. 2021 Oct;28(10):5544-5552. (PMID: 34287787)
Br Med J. 1962 Jul 28;2(5299):213-21. (PMID: 13870135)
Cancer. 2020 Apr 1;126(7):1559-1567. (PMID: 31840240)
BMC Cancer. 2019 Nov 12;19(1):1091. (PMID: 31718602)
Breast Cancer Res Treat. 2020 Feb;180(1):227-235. (PMID: 31980967)
Jpn J Clin Oncol. 2014 Jun;44(6):611. (PMID: 24864272)
JCO Glob Oncol. 2020 Apr;6:679-687. (PMID: 32348160)
JCO Oncol Pract. 2021 May;17(5):e637-e644. (PMID: 33974834)
J Clin Oncol. 2023 May 10;41(14):2546-2560. (PMID: 36944149)
JAMA Surg. 2016 May 1;151(5):424-31. (PMID: 26629881)
Eur J Surg Oncol. 2019 Aug;45(8):1364-1372. (PMID: 30837102)
Breast Cancer Res Treat. 2023 Jan;197(1):177-187. (PMID: 36334190)
Curr Oncol. 2022 Apr 08;29(4):2539-2549. (PMID: 35448182)
J Am Coll Surg. 2013 Mar;216(3):428-37. (PMID: 23357724)
Ann Surg Oncol. 2021 Nov;28(12):7441-7449. (PMID: 34050430)
Ann Surg. 2022 Apr 1;275(4):784-792. (PMID: 32657941)
Ann Surg Oncol. 2021 Sep;28(9):5048-5057. (PMID: 33532878)
CA Cancer J Clin. 2022 Nov;72(6):524-541. (PMID: 36190501)
JCO Oncol Pract. 2021 Oct;17(10):594-604. (PMID: 34077236)
J Clin Oncol. 2005 Jul 1;23(19):4265-74. (PMID: 15911866)
Ann Surg Oncol. 2021 Apr;28(4):2146-2154. (PMID: 32946012)
J Am Coll Surg. 2021 Dec;233(6):742-751.e5. (PMID: 34530124)
Breast Cancer. 2021 Mar;28(2):387-397. (PMID: 33044617)
JAMA Oncol. 2017 Dec 1;3(12):1722-1728. (PMID: 28241198)
Ann Surg Oncol. 2019 Jun;26(6):1604-1612. (PMID: 30737668)
Br J Cancer. 1959 Mar;13(1):20-5. (PMID: 13662489)
Ann Surg. 2019 Mar;269(3):537-544. (PMID: 29227346)
Lancet Oncol. 2015 Oct;16(13):1380-8. (PMID: 26363985)
N Engl J Med. 2001 Mar 15;344(11):783-92. (PMID: 11248153)
معلومات مُعتمدة: K12 AR084231 United States AR NIAMS NIH HHS; P30 CA014236 United States CA NCI NIH HHS; K12AR084231 United States GF NIH HHS; P30CA014236 United States GF NIH HHS
فهرسة مساهمة: Keywords: Breast cancer; Metastatic; Outcomes; Stage IV; Survival
تواريخ الأحداث: Date Created: 20240304 Date Completed: 20240517 Latest Revision: 20240520
رمز التحديث: 20240520
مُعرف محوري في PubMed: PMC11102301
DOI: 10.1007/s10549-024-07265-2
PMID: 38438700
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7217
DOI:10.1007/s10549-024-07265-2